Xue Shen

Xue Shen

Auto-generated profile, based on publicly available information

Xue Shen

Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China; Institute of Nephrology, Peking University, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China; Beijing Key Laboratory of Precision Medicine and New-drug/ Equipment Development for Severe Kidney Disease, Beijing, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2024 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
XSXue Shen
Xue Shen
PCPei Chen
Pei Chen
MLMuqing Liu
Muqing Liu
LLLijun Liu
Lijun Liu
SSSufang Shi
Sufang Shi
HZHong Zhang
Hong Zhang
The long-term prognosis of IgA nephropathy (IgAN) and the optimal target for proteinuria treatment remain controversial. This study, utilizing a large prospective cohort from China, aims to assess the long-term outcomes of IgAN and to explore the definition of proteinuria remission. We enrolled 2 141 patients with biopsy-proven IgAN, all with at least 12 months of follow-up, from a prospective IgAN cohort at Peking University First Hospital. We utilized Kaplan-Meier analysis, Cox regression, and an eGFR slope calculated via a linear mixed model to investigate kidney outcomes. The median (Q1, Q3) baseline proteinuria was 1.26 (0.65, 2.40) g/d, and the estimated GFR was 80 (52, 103) mL/min/1.73m2. After a mean follow-up of 5.8 (±4.4) years, 509 (24%) patients progressed to end-stage kidney disease (ESKD). The median kidney survival time was 12.4 years, the annual event rate of ESKD was 41.1 per 1000 person-years, and the 15-year kidney survival rate was 40%. Time-averaged proteinuria level was strongly associated with kidney failure (adjusted HR: 1.76, 95%CI: 1.65 to 1.88). Restriction cubic spline analysis indicated that the risk of ESKD increases rapidly when time-average proteinuria exceeded 0.5 g/d. There was no significant difference in long-term kidney survival between patients with proteinuria < 0.3 g/d and those with 0.3–0.5 g/d, with both groups demonstrating a better prognosis. The long-term outcomes for patients with IgAN under current treatment strategies remain poor, with most progressing to ESKD within 15 years. Patients with time-averaged proteinuria ≥ 0.5 g/d experience worse kidney outcomes, challenging the previous view that proteinuria < 1.0 g/d was associated with a low risk of kidney failure.

1 July 2025 in Clinical Kidney Journal
Verified
Journal Article
Open access
QCQinlan Chen
Qinlan Chen
PCPei Chen
Pei Chen
RHRong He
Rong He
JZJincan Zan
Jincan Zan
XSXue Shen
Xue Shen
HZHong Zhang
Hong Zhang
Background: Targeted release formulation (TRF)-budesonide (Nefecon), targeting galactose-deficient IgA1 (Gd-IgA1) production and IgA immune complex formation, has been approved for IgA nephropathy (IgAN) treatment. In this study we explored whether early changes of these biomarkers can predict the clinical response to Nefecon therapy. Methods: Plasma samples from 27 IgAN patients treated with Nefecon and followed at least 6 months were collected during routine visits. We measured the levels of Gd-IgA1 and poly-IgA during the treatment, analyzing the association between their baseline levels or changes and proteinuria reduction. Results: The mean proteinuria level was 1.3 ± 0.8 g/d and estimated glomerular filtration rate (eGFR) was 47.1 ± 21.7 mL/min per 1.73 m² at baseline. During the follow-up, proteinuria slowly reduced with the alterations of -0.12 g/d, -0.42 g/d, -0.58 g/d, and –0.86 g/d at 3rd, 6th, 9th and 12th months, respectively. The plasma levels of Gd-IgA1, poly-IgA and total IgA decreased after Nefecon treatment with an obvious decline at 2 months in Gd-IgA1 by -1067.3 ng/ml, and poly-IgA by -1.18 mg/l. All biomarker reductions were strongly associated with proteinuria decrease (P < 0.0001). Importantly, the early reduction in poly-IgA during the first 2 months was associated with proteinuria reduction at 6 months (R = 0.47, P = 0.01). Similar trends were observed for Gd-IgA1 though not statistically significant. Conclusions: The early changes in Gd-IgA1 or poly-IgA, especially poly-IgA, were associated with future proteinuria reduction, supporting the potential of Gd-IgA1 and poly-IgA as biomarkers for predicting Nefecon response in IgAN.

7 August 2025 in Clinical Kidney Journal
Verified
Journal Article
Open access
XSXue Shen
Xue Shen
PCPei Chen
Pei Chen
LLLijun Liu
Lijun Liu
SSSufang Shi
Sufang Shi
XZXujie Zhou
Xujie Zhou
HZHong Zhang
Hong Zhang
Background: The International IgA Nephropathy Prediction Tools using clinical variables and the Oxford MEST scores were developed in outdated cohorts. External validation is required to assess the tool's applicability in predicting progression risk for patients on novel therapies. Methods: We included 677 immunoglobulin A nephropathy (IgAN) patients (Peking University First Hospital, 2003–23) treated with endothelin receptor antagonists, Nefecon, sodium-glucose cotransporter 2 inhibitors, hydroxychloroquine or telitacicept, a BAFF/APRIL inhibitor. The primary outcome was defined as a 50% decline in estimated glomerular filtration rate or end-stage kidney disease. Discrimination (C-statistic), calibration [calibration slope, Integrated Calibration Index (ICI)], model fit (R2D) and risk stratification (Kaplan–Meier curves) were assessed. Results: The median follow-up was 4.8 years (interquartile range 2.2, 8.1), and 190 (28.1%) patients experienced the primary outcome, with a 5-year risk of 9.8%. Compared with the median biopsy year of reported cohorts of original model, our cohort is more contemporary (2017). We validated both original and updated models (and for full model with and without race version). All versions showed adequate discrimination, poor calibration and model fit: C-statistic ∼0.74, calibration slope ∼0.50, R2D 0.10, and poor separation of Kaplan–Meier curves, except for the highest-risk group. The tools consistently overestimated risk in patients receiving novel therapies. These findings further demonstrated that novel therapies can improved clinical outcomes for IgAN patients. Conclusions: In this study, both versions of both models demonstrated limited performance and overestimated risks. Given the prognostic improvement with novel IgAN therapies, these prediction tools may need updating for use in currently treated patients.

22 May 2026 in Kidney International
Verified
Journal Article
Open access
XSXue Shen
Xue Shen
CSChutian Shu
Chutian Shu
YDYaping Dong
Yaping Dong
JLJingyi Li
Jingyi Li
RLRun Li
Run Li
JLJicheng Lv
Jicheng Lv
IgA nephropathy is the most common primary glomerulonephritis worldwide, characterized by IgA deposition and a high risk of progression to kidney failure. While emerging therapies target IgA production or downstream inflammation, strategies to directly clear established IgA deposits from the kidney remain underexplored. Here, we evaluate a novel therapeutic IgA protease for its ability to clear glomerular IgA deposits and restore normal histology. The recombinant IgA protease was derived from Thomasclavelia ramosa (strain AK183), a human commensal bacterium presumed to have evolved for mutual tolerance within the microbiome with the host. The enzyme was PEGylated to reduce immunogenicity and prolong its half-life, producing the drug product PEG-AK183. We characterized its ex vivo potency and pharmacokinetic-pharmacodynamic profile in mice and then assessed therapeutic efficacy over eight weeks. In vitro, a single molecule of PEG-AK183 cleaved between 500 and 1000 hIgA1 molecules in 60 minutes, demonstrating high catalytic efficiency. A single injection into human IgA1 (hIgA1) transgenic mice induced complete clearance of serum hIgA1 for up to eight days. Following eight-week weekly treatments, PEG-AK183 reduced circulating IgA and immune complex levels by approximately 80% and completely cleared glomerular IgA and associated complement C3 deposits. This was accompanied by a 45.5% reduction in proteinuria and significant improvements in histopathological indices, including mesangial proliferation and endocapillary hypercellularity. No treatment-related adverse effects were observed, including abnormalities in intestinal plasma B cells, hepatotoxicity, or the anti-drug antibody development, supporting a favorable safety profile for long-term, repeated administration. Our preclinical study demonstrated that the engineered IgA degrader PEGAK183 is a potent, effective, and safe therapeutic in a humanized IgA nephropathy mouse model. By achieving sustained clearance of pathogenic IgA from both circulation and glomerular deposits, this IgA-protease-based therapy represents a promising candidate for the future treatment of IgA nephropathy.